Formulation and evaluation of novel aspirin nanoparticles loaded suppositories

doi:10.5246/jcps.2013.03.037

Formulation and evaluation of novel aspirin nanoparticles loaded suppositories

Ravi Sankar V.^*, Dhachinamoorthi D., Chandra Shekar K.B.

1. Department of Pharmaceutics, C.E.S College of Pharmacy, Kurnool 51812, India
2. Departments of Pharmaceutics, Q.I.S College of Pharmacy, Ongole 523002, India
3. Department of Chemistry, J.N.T.A University, Anantapur 515005, India

收稿日期:2012-11-12 修回日期:2013-02-25 出版日期:2013-05-08 发布日期:2013-05-08
通讯作者: Ravi Sankar V.*

Formulation and evaluation of novel aspirin nanoparticles loaded suppositories

Ravi Sankar V.^*, Dhachinamoorthi D., Chandra Shekar K.B.

1. Department of Pharmaceutics, C.E.S College of Pharmacy, Kurnool 51812, India
2. Departments of Pharmaceutics, Q.I.S College of Pharmacy, Ongole 523002, India
3. Department of Chemistry, J.N.T.A University, Anantapur 515005, India

Received:2012-11-12 Revised:2013-02-25 Online:2013-05-08 Published:2013-05-08
Contact: Ravi Sankar V.*

摘要/Abstract

摘要：

The main objective of the present work is to design aspirin nanoparticles loaded suppositories which will reduce the side effects caused by aspirin suppositories. Aspirin nanoparticles were prepared initially based on ionic-gelation mechanism and lyophilized. The prepared nanoparticles were evaluated, and the results confirmed that Fa9 formulation was the best with greater drug entrapment efficiency. Aspirin suppositories were prepared in order to investigate the best base composition. The prepared suppositories were evaluated and FS1, FS3, FS4, FS8, FS11, and FS12 were proved to be the best base compositions based on dissolution performed. The lyophilized aspirin nanoparticles of Fa9 were used to prepare aspirin nanoparticles loaded suppositories. The in vitro results revealed that Fas11 was the best formulation.

关键词: Suppositories, Ionic-gelation method, Rectal carcinoma, Aspirin, Lyophilization

Abstract:

Key words: Suppositories, Ionic-gelation method, Rectal carcinoma, Aspirin, Lyophilization

中图分类号:

R943

Supporting: ^*Corresponding author. Tel.: +919494422695

Ravi Sankar V.^*, Dhachinamoorthi D., Chandra Shekar K.B.. Formulation and evaluation of novel aspirin nanoparticles loaded suppositories [J]. , DOI: 10.5246/jcps.2013.03.037.

参考文献

[1] Shu, X.Z.; Zhu, K.J.; Shu, X.Z. Eur. J. Pharm. Biopharm. 2002, 54, 235-243.
[2] Berger, J.; Reist, M.; Mayer, J.M.; Felt, O.; Peppas, N.A.; Gurny, R. Eur. J. Pharm. Biopharm. 2004, 57, 19-34.
[3] Boonsongrit, Y.; Mitrevej, A.; Mueller, W. Eur. J. Pharm. Biopharm. 2006, 62, 267-274.
[4] Kang, M.L.; Kang, S.G.; Jiang, H.L.; Shin, S.W.; Lee, D.Y.; Ahn, J.M.; Rayamahji, N.; Park, I.K.; Shin, S.J.; Cho, C.C.S.; Yoo, H.S. Eur. J. Pharm. Biopharm. 2006, 63, 215-220.
[5] Motwani, S.K.; Chopra, S.; Talegaonkar, S.; Kohli, K.; Ahmad, F.J.; Khar, R.K. Eur. J. Pharm. Biopharm. 2008, 68, 513-525.
[6] Guo, C.; Gemeinhart, A. Eur. J. Pharm. Biopharm. 2008, 70, 597-604.
[7] Sadeghi, A.M.M.; Dorkoosh, F.A.; Avadi, M.R.; Weinhold, M.; Bayat, A.; Delie, F.; Gurny, R.; Larijani, B.; Rafiee-Tehrani, M.; Junginger, H.E. Eur. J. Pharm. Biopharm. 2008, 70, 270-278.
[8] Wanga, W.; Luo, C.; Shao, S.; Zhou, S. Eur. J. Pharm. Biopharm. 2010, 76, 376-383.
[9] Lemarchand, C.; Gref, R.; Couvreur, P. Eur. J. Pharm. Biopharm. 2004, 58, 327-341.
[10] Hermann, T.W. Int. J. Pharm. 1995, 123, 1-11.
[11] Schoonen, A.J.M.; Moolenaar, F.; Huizinga, T. Int. J. Pharm. 1979, 4, 141-152.
[12] Muynck, C.D.; Lefebvre, R.A.; Remon, J.P. Int. J. Pharm. 1994, 104, 87-91.
[13] Gjellan, K.C.; Graffnef, R. Int. J. Pharm. 1994, 104, 215-226.
[14] Choi, H.G.; Oh, Y.K.; Kim, C.K. Int. J. Pharm. 1998, 165, 23-32.
[15] Ibrahim, S.A.; El-Faham, T.H.; Shawky, S.; Tous, E.M. Int. J. Pharm. 1990, 61, 1-7.
[16] http://www.medicinenet.com/aspirin-rectal_suppository/article.htm
[17] Calvo, P.; Remunan-Lopez, C.; Vila-Jato, J.L.; Alonso, M.J. J. Appl. Polym. Sci. 1997, 63, 125-132.
[18] Oyarzun-Ampuero, F.A.; Brea, J.; Loza, M.I.; Torres, D.; Alonso, M.J. Int. J. Pharm. 2009, 381, 122-129.
[19] Pryce-Jones, R.H.; Eccleston, G.M.; Abu-Bakar, B.B. Int. J. Pharm. 1992, 86, 231-237.
[20] Güner, T.; Arici, M.; Ertan, G. J. Pharm. Sci. 2004, 29, 177-184.
[21] Motwani, S.K.; Chopra, S.; Talegaonkar, S.; Kohli, K.; Ahmad, F.J.; Khar, R.K. Eur. J. Pharm. Biopharm. 2008, 68, 513-525.
[22] Oyarzun-Ampuero, F.A.; Brea, J.; Loza, M.I.; Torres, D.; Alonso, M.J. Int. J. Pharm. Sci. 2009, 381, 122-129.
[23] Jain, A.K.; Khar, R.K.; Ahmed, F.J.; Diwan, P.V. Eur. J. Pharm. Biopharm. 2008, 69, 426-435.
[24] Nafee, N.; Schneider, M.; Schaefer, U.F.; Lehr, C.M. Int. J. Pharm. 2009, 381, 130-139.
[25] Güner, T.; Mesut Arici, M.; Grtan, G. J. Pharm. Sci. 2004, 29, 177-184.
[26] Çaliş, S.; Şumnu, M.; Hincal, A.A. Pharmazie. 1994, 49, H. 5.
[27] Choi, H.G.; Oh, Y.K.; Kim, C.K. Int. J. Pharm. 1998, 165, 23-32.
[28] Siewert, M.; Dressman, J.; Brown, C.K.; Shah, V.P. 2003, January fip/aaps J. 14.
[29] Siepmann, J.; Siepmann, F. Int. J. Pharm. 2008, 364, 328-343.

Formulation and evaluation of novel aspirin nanoparticles loaded suppositories

Formulation and evaluation of novel aspirin nanoparticles loaded suppositories

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价